Why Abbvie Might Be Poised for a Return to Profitability
In this clip from "The Pharma & Biotech Show" on Motley Fool Live, recorded on Feb. 2, Motley Fool contributors Keith Speights and Brian Orelli assess the pharma giant's projection that it'll return to growth quickly in the second half of the decade.
Keith Speights: Here's the statement that really jumped out to me, Brian. I'm going to read this, "AbbVie (NYSE: ABBV) confirmed prior revenue guidance of greater than $15 billion in combined Skyrizi and Rinvoq risk-adjusted sales in 2025. AbbVie expects each asset to deliver risk-adjusted sales of greater than $7.5 billion in 2025."
Source Fool.com
